The Wall Street Journal examines "big pharma's growing interest in a corner of healthcare - emerging-market inoculations," in light of a recent move by Novartis to purchase an 85 percent stake in the Chinese vaccine maker Zhejiang Tianyuan Bio-Pharmaceutical Co.
The Wall Street Journal examines how the relationship between some doctors and device makers leads to big payments - often from Medicare. Meanwhile, ProPublica explores other conflict of interest issues. The Wall Street Journal: Top... Read Post
The Wall Street Journal examines a $1.5 billion program supported by Italy, the U.K. Read Post